SD HEALTHCARERecent and archived news stories on: Biotechnology, Doctors, Drugs, Health Insurance, HMO's/PPO's, Hospitals, Medical Devices, Nursing...
A federal jury in Florida on June 16 decided that San Diego-based Millennium Laboratories violated laws against kickbacks by giving physicians free urine testing cups, and it awarded a Baltimore-based competitor nearly $15 million in mostly punitive damages.
A federal jury in Florida on Tuesday decided that San Diego-based Millennium Laboratories violated laws against kickbacks by giving physicians free urine testing cups, and it awarded a Baltimore-based competitor nearly $15 million in mostly punitive damages.
CareFusion announced the commercial launch of its new micro-laparoscopic line of surgical instruments.
La Jolla Pharmaceutical Co. has signed an option agreement with Stanford University that will add proprietary technology to its programs, the pharma company said.
Debt financing follows $15 million equity financing.
OncoSec Medical Inc. reported a net loss of $8.5 million, or $0.05 per share, for the nine months ended April 30, 2014.
Sorrento Therapeutics Inc. announced that the underwriters of its previously announced public offering of 4,765,000 shares of its common stock have exercised in full their option to purchase an additional 714,750 shares of common stock from the company at $5.25 per share.
San Diego-based Organovo Holdings Inc. reported revenues of $400,000 for the fiscal year ending March 31, 2014 compared with revenues of $1.2 million for the year ended Dec. 31, 2012.
Intercare Insurance Solutions, a HUB International Co., is holding a Corporate Wellness Symposium June 19.
(Editor’s note: This is the final column on biotechnology and health care from Meghana Keshavan, who leaves the San Diego Business Journal as of this issue to join a national online publication focused on innovation in the health care industry.)
Biotech: Company Sees Huge Market for Biosimilars As Patents on Biologics End
Pfenex Inc., a spinoff of Dow Chemical Co., is the latest San Diego biotech to file for an initial public offering. The company is looking to raise $74.8 million as it focuses development on a growing class of drugs called biosimilars, which are projected to make a large dent in big pharma sales as patents for biologic drugs expire.
Possible approval of weight-loss drug pushed back to September.
The property was fully leased.
The San Diego Business Journal is now accepting nominations for 2014 Healthcare Champions awards, which honors individuals within the San Diego community who have demonstrated exceptional leadership and innovation in the health care industry.
Former home of La Jolla drug store was bought.